市場調查報告書

多發性骨髓瘤(MM)治療市場:全球行業趨勢,佔有率,規模,增長,機會,預測(2020-2025)

Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

出版商 IMARC Services Private Limited 商品編碼 952901
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
多發性骨髓瘤(MM)治療市場:全球行業趨勢,佔有率,規模,增長,機會,預測(2020-2025) Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025
出版日期: 2020年07月18日內容資訊: 英文 114 Pages
簡介

2014年至2019年,全球多發性骨髓瘤(MM)治療市場的複合年增長率約為9%。隨著血液癌的增加,醫學領域的顯著發展是推動該市場增長的重要因素之一。多發性骨髓瘤通常由特定的遺傳異常引起,在這種遺傳異常中,藥物被用來調節免疫系統並提高化學療法,放射療法,幹細胞移植和血小板輸注的效率。市場上也有各種技術進步,例如增強了消費者對使用生物免疫系統識別和攻擊骨髓瘤細胞的生物治療劑的益處的認識,以及開發了microRNA治療劑和納米藥物。支持增長。預計醫療成本上漲和醫學領域廣泛的研發(R&D)活動等因素將進一步推動市場。

該報告調查了全球多發性骨髓瘤(MM)治療市場,包括市場表現,按治療/藥物類型最終用戶/分銷渠道/地區進行的市場分析,競爭格局以及主要公司的概況。我們提供諸如此類的信息。

目錄

第1章前言

第2章範圍和調查方法

第3章執行摘要

第4章簡介

第5章世界市場

  • 市場概況
  • 市場表現

第6章市場細分:按療法

  • 靶向治療
  • 生物療法
  • 化學療法
  • 其他

第7章市場細分:按藥物類型

  • 免疫調節劑
  • 蛋白□體抑製劑
  • 組蛋白脫乙□基□抑製劑
  • 單克隆抗體藥物
  • 類固醇
  • 其他

第8章市場細分:按最終用戶

  • 男性
  • 女性

第9章市場細分:按分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥房
  • 其他

第10章市場細分:按地區

  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞
    • 印度尼西亞
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 按國家

第11章SWOT分析

第12章價值鏈分析

第13章波特的五力分析

第14章價格指數

第15章競爭情況

  • 市場結構
  • 主要公司
  • 主要公司簡介
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • DAIICHI SANKYO COMPANY
    • Genzyme Corporation (Sanofi-Aventis)
    • Johnson & Johnson Services Inc.
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Pharma Mar S.A.
    • Takeda Pharmaceutical Company Limited.
    • Teva Pharmaceutical Industries Ltd.
目錄
Product Code: SR1019K35_Report

The global multiple myeloma drugs market grew at a CAGR of around 9% during 2014-2019. Multiple myeloma, or Kahler's disease, refers to a form of blood cancer that primarily affects the plasma cells. Some of the most common types of multiple myeloma drugs include chemotherapeutic agents, corticosteroids and immunomodulatory agents. These pharmaceutical drugs aid in promoting bone healing, prevent hypercalcemia, bone fracture, spinal cord compression and anemia, while minimizing the need for chemotherapy. The chemotherapeutic agents include various anthracycline antibiotics and alkylating agents, such as melphalan, doxorubicin, vincristine and liposomal doxorubicin. The targeted therapy drugs include proteasome inhibitor, such as bortezomib, and various other compounds, including dexamethasone, prednisone and thalidomide.

Significant developments in the healthcare sector, along with the increasing prevalence of hematological cancer, is one of the key factors driving the growth of the market. Multiple myeloma is usually caused by specific genetic abnormalities, and the treatment of this disease involves drugs that modulate the immune system and aid in enhancing the efficiency of chemotherapies, radiation therapies, stem cell transplants and platelet transfusion. Furthermore, rising consumer awareness regarding the benefits of biologic therapy drugs, which utilize the body's immune system to identify and attack the myeloma cells, is also providing a boost to the market growth. Additionally, various technological advancements, such as the development of microRNA therapeutics and nanomedicines for the treatment of multiple myeloma, is acting as another growth-inducing factor. These medicines are used to facilitate the delivery of macromolecular agents into the bone marrow and catalyze antitumor responses. Other factors, including the rising healthcare expenditures and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further. Looking forward, IMARC Group expects the market to witness moderate growth during the next five years.

Breakup by Therapy:

  • Targeted Therapy
  • Biologic Therapy
  • Chemotherapy
  • Others

Breakup by Drug Type:

  • Immunomodulatory Drugs
  • Proteasome Inhibitors
  • Histone Deacetylase Inhibitors
  • Monoclonal Antibody Drugs
  • Steroids
  • Others

Breakup by End-User:

  • Men
  • Women

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Genzyme Corporation (Sanofi-Aventis), Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., Pharma Mar S.A., Takeda Pharmaceutical Company Limited., Teva Pharmaceutical Industries Ltd., etc.

Key Questions Answered in This Report:

  • How has the global multiple myeloma drugs market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What is the breakup of the market based on the therapy?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the end-user?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global multiple myeloma drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Multiple Myeloma Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Market Forecast

6 Market Breakup by Therapy

  • 6.1 Targeted Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Biologic Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Chemotherapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Immunomodulatory Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Proteasome Inhibitors
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Histone Deacetylase Inhibitors
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Monoclonal Antibody Drugs
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Steroids
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by End-User

  • 8.1 Men
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Women
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Indicators

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Amgen Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bristol-Myers Squibb Company
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 DAIICHI SANKYO COMPANY
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Genzyme Corporation (Sanofi-Aventis)
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 SWOT Analysis
    • 15.3.5 Johnson & Johnson Services Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Merck & Co. Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Novartis AG
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Pfizer Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pharma Mar S.A.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
    • 15.3.10 Takeda Pharmaceutical Company Limited.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Teva Pharmaceutical Industries Ltd.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Multiple Myeloma Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Multiple Myeloma Drugs Market: Sales Value (in Billion US$), 2014-2019
  • Figure 3: Global: Multiple Myeloma Drugs Market: Breakup by Therapy (in %), 2019
  • Figure 4: Global: Multiple Myeloma Drugs Market: Breakup by Drug Type (in %), 2019
  • Figure 5: Global: Multiple Myeloma Drugs Market: Breakup by End-User (in %), 2019
  • Figure 6: Global: Multiple Myeloma Drugs Market: Breakup by Distribution Channel (in %), 2019
  • Figure 7: Global: Multiple Myeloma Drugs Market: Breakup by Region (in %), 2019
  • Figure 8: Global: Multiple Myeloma Drugs Market Forecast: Sales Value (in Billion US$), 2020-2025
  • Figure 9: Global: Multiple Myeloma Drugs (Targeted Therapy) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 10: Global: Multiple Myeloma Drugs (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 11: Global: Multiple Myeloma Drugs (Biologic Therapy) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 12: Global: Multiple Myeloma Drugs (Biologic Therapy) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 13: Global: Multiple Myeloma Drugs (Chemotherapy) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 14: Global: Multiple Myeloma Drugs (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 15: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 16: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 17: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 18: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 19: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 20: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 21: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 22: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 23: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 24: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 25: Global: Multiple Myeloma Drugs (Steroids) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 26: Global: Multiple Myeloma Drugs (Steroids) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 27: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 28: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 29: Global: Multiple Myeloma Drugs (Men) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 30: Global: Multiple Myeloma Drugs (Men) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 31: Global: Multiple Myeloma Drugs (Women) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 32: Global: Multiple Myeloma Drugs (Women) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 33: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 34: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 35: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 36: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 37: Global: Multiple Myeloma Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 38: Global: Multiple Myeloma Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 39: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 40: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 41: North America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 42: North America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 43: United States: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 44: United States: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 45: Canada: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 46: Canada: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 47: Asia Pacific: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 48: Asia Pacific: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 49: China: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 50: China: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 51: Japan: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 52: Japan: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 53: India: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 54: India: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 55: South Korea: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 56: South Korea: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 57: Australia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 58: Australia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 59: Indonesia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 60: Indonesia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 61: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 62: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 63: Europe: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 64: Europe: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 65: Germany: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 66: Germany: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 67: France: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 68: France: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 69: United Kingdom: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 70: United Kingdom: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 71: Italy: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 72: Italy: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 73: Spain: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 74: Spain: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 75: Russia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 76: Russia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 77: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 78: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 79: Latin America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 80: Latin America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 81: Brazil: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 82: Brazil: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 83: Mexico: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 84: Mexico: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 85: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 86: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 87: Middle East and Africa: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 88: Middle East and Africa: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 89: Global: Multiple Myeloma Drugs Industry: SWOT Analysis
  • Figure 90: Global: Multiple Myeloma Drugs Industry: Value Chain Analysis
  • Figure 91: Global: Multiple Myeloma Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Multiple Myeloma Drugs Market: Key Industry Highlights, 2019 and 2025
  • Table 2: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Therapy (in Million US$), 2020-2025
  • Table 3: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2020-2025
  • Table 4: Global: Multiple Myeloma Drugs Market Forecast: Breakup by End-User (in Million US$), 2020-2025
  • Table 5: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2020-2025
  • Table 6: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Region (in Million US$), 2020-2025
  • Table 7: Global: Multiple Myeloma Drugs Market Structure
  • Table 8: Global: Multiple Myeloma Drugs Market: Key Players